Parabilis Medicines, a clinical-stage biopharmaceutical company, has secured $3.0 billion in new funding from investors. This significant capital infusion will support the company's mission to develop innovative medicines for people living with cancer. Parabilis Medicines is known for its pioneering Helicon™ discovery platform, which engineers precisely-tuned, stabilized helical peptide therapeutics designed to target traditionally undruggable proteins.
The company's approach aims to unlock a large number of challenging targets relevant to various cancers. Its lead clinical program, FOG-001, is a first-in-class TCF-blocking β-catenin inhibitor currently being evaluated in a Phase 1/2 study for patients with colorectal cancer and other solid tumors. This program serves as a key validation of the Helicon™ platform's ability to address undruggable intracellular protein-protein targets.
Beyond FOG-001, Parabilis Medicines is advancing a pipeline of other first-in-class programs targeting proteins considered intractable with traditional drug modalities. The versatility of the Helicon™ platform allows for the discovery of multiple targeting mechanisms, including functional protein-protein interaction inhibitors, bifunctional degraders, and radioligand therapeutics. The newly raised capital is expected to be deployed to accelerate the development of these clinical and preclinical programs, expand research and development capabilities, and support broader growth initiatives.
This funding round underscores investor confidence in Parabilis Medicines' platform and pipeline. The company, headquartered in Cambridge, Mass., is now well-positioned to further its efforts in bringing novel therapeutic options to cancer patients and expanding its impact within the biopharmaceutical landscape.
